Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

RCT (n=175) found that more children with peanut allergy given AR101 oral immunotherapy tolerated a food challenge (1000 mg peanut protein) than those given placebo (58% vs 2%, p<0.0001). Adverse event rates were similar.

Source:

The Lancet Child and Adolescent Health